Top
About the Journal

Cancer Drug Resistance (CDR) is an international peer-reviewed, open access, online journal.

Aims and Scope

Cancer Drug Resistance is a quarterly published journal committed to the rapid publication of high quality, peer-reviewed, original research. The journal publishes research articles, reviews, case reports, commentaries and letters on pharmacological aspects of drug resistance and its reversal, including drug design, drug delivery, drug distribution and cellular drug resistance. Molecular mechanisms of drug resistance also cover the cellular pharmacology of drug resistance such as influx and efflux pumps (including the ABC pumps), receptors and their ligands, cellular signaling pathways, drug activation and degradation (including Phase I and II metabolism), drug sequestration, target modification and DNA repair. Drug classes to be covered include DNA targeted drugs and antihormones as well as antibodies and protein kinase inhibitors. Both clinical and experimental aspects of drug resistance in cancer are included. 

Ownership

The journal is owned by OAE Publishing Inc.

Open Access

All articles published by CDR are made freely and permanently accessible online immediately from the date of publication. For further information, please refer to Open Access. Articles are published under a Creative Commons Attribution 4.0 International License (CC BY). The CC BY allows for maximum dissemination and re-use of open access materials and is preferred by many research funding bodies. Under this license users are free to share (copy, distribute and transmit) and remix (adapt) the contribution for any purposes, even commercially, provided that the users appropriately acknowledge the original authors and the source.
Authors retain the copyright of their works as well as the rights to make certain uses of the works.

Editorial Board

For more information about the editorial team, please refer to Editorial Board.

Editorial Policies

All manuscripts submitted to CDR should adhere to OAE's Editorial Policies.

Peer Review

The journal adheres to rigorous peer review process and undergoes single-blind peer review. For more details, please refer to Editorial Process and Peer Review Guidelines.

Publication Ethics Statement

Cancer Drug Resistance is a member of the Committee on Publication Ethics (COPE). We fully adhere to its Code of Conduct and to its Best Practice Guidelines.

The editors of this journal enforce a rigorous peer-review process together with strict ethical policies and standards to ensure to add high quality scientific works to the field of scholarly publication. Unfortunately, cases of plagiarism, data falsification, image manipulation, inappropriate authorship credit, and the like, do arise. The editors of Cancer Drug Resistance take such publishing ethics issues very seriously and are trained to proceed in such cases with a zero tolerance policy. To verify the originality of content submitted to our journals, we use CrossCheck (powered by iThenticate) to check submissions against previous publications.

Journal Information and Statistics

  • Launch date: 19 March 2018
  • Publication model: Open access
  • ISSN 2578-532X (Online)
  • Digital archive: Portico
  • Frequency: Quarterly published
  • DOI: 10.20517/cdr

Contact

Please visit Contact Us for details about different queries.